News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 22, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Nov 2, 2023
-- Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary safety and anti-tumor activity data...
-
Sep 5, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Aug 16, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Aug 3, 2023
Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with...
-
Jul 13, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Jun 8, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Jun 8, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Jun 3, 2023
Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation...
-
May 15, 2023
Partner CSPC Pharmaceutical Group Limited's ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussion at ASCO 2023 Presented EO-3021 preclinical...
-
Apr 26, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Apr 17, 2023
EO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 EO-3021 induced a confirmed partial response in a patient with metastatic gastric cancer...
-
Mar 14, 2023
- Company plans to highlight preclinical proof-of-concept data for EO-3021 in an oral presentation at the New Drugs on the Horizon special session NEW YORK, March 14, 2023 /PRNewswire/ --...
-
Mar 9, 2023
Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023 Announced pipeline prioritization...
-
Mar 1, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Feb 8, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Jan 9, 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...
-
Jan 6, 2023
Prioritizing the development of EO-3021, a potential best-in-class ADC targeting Claudin18.2, and additional pipeline programs including those through its existing partnership with Caris Life Sciences
-
Nov 30, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Nov 3, 2022
On track to report additional interim seribantumab data from the Phase 2 CRESTONE study in the first half of 2023 Preparations are underway to initiate a Phase 1 clinical trial of EO-3021 in the...
-
Aug 4, 2022
Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across all tumor types harboring NRG1 fusions...
-
Aug 3, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Jul 28, 2022
Initial tranche supports the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and execution of Company's pipeline NEW YORK, July 28, 2022...
-
Jul 28, 2022
Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801) Expands pipeline to now include two clinical stage precision oncology candidates for...
-
Jun 1, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
May 26, 2022
Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions Clinical activity observed includes a 33% response...
-
May 25, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
May 5, 2022
Initial seribantumab clinical data from Phase 2 CRESTONE study selected for oral presentation at ASCO 2022 David Dornan, PhD appointed Chief Scientific Officer, bringing deep oncology R&D and drug...
-
Apr 27, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Mar 14, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Mar 3, 2022- On track to present initial clinical data from Cohort 1 of the Phase 2 CRESTONE study in mid-2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Mar 1, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Jan 10, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today...
-
Jan 6, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Jan 5, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Nov 18, 2021
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Nov 12, 2021- Global Expansion of the Phase 2 CRESTONE Study into Canada and Australia
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Oct 20, 2021
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Oct 14, 2021The Cancer Molecular Screening and Therapeutics (MoST) Study Highlights the Importance of Genomic Tumor Testing to Match Patients with Targeted Oncology Agents
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Sep 7, 2021
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Aug 12, 2021- Entered into collaboration with Caris Life Sciences for the identification of oncogenic fusions and driver alterations -
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Aug 4, 2021
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Jun 24, 2021
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Jun 17, 2021
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the appointment of...
-
Jun 15, 2021
Two precision medicine innovators to leverage genomic data from leading molecular diagnostics platform to identify actionable driver alterations, and jointly discover and develop therapeutics to...
-
May 18, 2021
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the appointment of...
-
Apr 10, 2021- Results further support the investigation of monotherapy seribantumab for the treatment of solid tumors uniquely driven by an NRG1 fusion in the ongoing Phase 2 CRESTONE study -
Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the presentation by...
-
Apr 6, 2021- Results show seribantumab efficiently inhibited HER3 and the entire ERBB family signaling pathway and established a biologically effective dose range for tumors driven by an NRG1 fusion -
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the publication in...
-
Mar 16, 2021Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels
Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, Inc. (NASDAQ:NEO),...
-
Jan 6, 2021
Elevation Oncology , a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today that Shawn M....